BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, September 23, 2023
Home » Blogs » BioWorld Perspectives » An Optimist’s Take on Funding Options for Small Biotechs

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

An Optimist’s Take on Funding Options for Small Biotechs

Nov. 15, 2011
By Trista Morrison
No Comments

No, that’s not a typo. I’m feeling optimistic about fundraising opportunities for small biotechs. Yes, I know we’re seeing venture firms pull back on an almost weekly basis (Prospect Ventures, Scale Venture Partners, etc.). And yes, I know the NVCA said VCs are fleeing life sciences. And yes, I know the initial public offering (IPO) window remains dubious at best.

BUT . . . there are some really interesting new options making their way through Congress, as anyone who read either BioWorld Insight or BioWorld Today on Monday already knows. For everyone else, here’s the low-down:

  • H.R. 1070 ? would provide an alternative to the IPO by letting private firms raise up to $50 million publicly and trade their shares, without the expense of becoming a reporting company (under current Regulation A rules, companies can only raise $5 million, which makes it hardly worth the trouble ? see more on that in BioWorld Insight next week)
  • H.R. 2930 ? would let private start-ups raise up to $2 million through crowd funding, essentially opening the private markets to non-accredited investors and perhaps providing just enough support to get that preclinical proof-of-concept data needed to hook a venture investor or a pharma partner
  • H.R. 2167 ? would let private companies have more shareholders before they have to start reporting to the SEC
  • H.R. 2940 ? would loosen the restrictions on advertising private financings
  • H.R. 3213 ? would expand the small company exemptions from Sarbanes-Oxley compliance
Does H.R. 1070 solve the problem of all those mid-stage biotechs stuck in venture portfolios with no exit? No. Does H.R. 2930 solve the valley of death? No. In both cases, it remains to be seen how much demand the public will have for risky biotech ventures (see, I can be a realist, too). But in both cases: at least the government is trying to give small companies some new options. And there’s a chance some of those companies might actually be able to make it work.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 22, 2023.
  • Hands holding torn contract

    Quite a fix: Orthofix sacks three top execs

    BioWorld MedTech
    Orthofix Medical Inc. terminated its CEO, chief financial officer and chief legal officer in a move that plunged the stock from $18.63 at Monday’s close to $13.01...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
  • New NLRP3 inflammasome inhibitors named in PTC Therapeutics patent

    BioWorld Science
    PTC Therapeutics Inc. has patented new NLRP3 inflammasome inhibitors reported to be useful...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing